Guardant Health [GH] vs Charles River [CRL] Detailed Stock Comparison
Guardant Health
NASDAQ
Loading...
Charles River
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Guardant Health wins in 8 metrics, Charles River wins in 10 metrics, with 0 ties. Charles River appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Guardant Health | Charles River | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -17.45 | 681.33 | Guardant Health |
| Price-to-Book Ratio | -25.24 | 2.16 | Guardant Health |
| Debt-to-Equity Ratio | -4.37 | 82.04 | Guardant Health |
| PEG Ratio | 3.66 | -17.28 | Charles River |
| EV/EBITDA | -20.38 | 10.35 | Guardant Health |
| Profit Margin (TTM) | -49.93% | -1.66% | Charles River |
| Operating Margin (TTM) | -45.75% | 16.67% | Charles River |
| EBITDA Margin (TTM) | N/A | 16.67% | N/A |
| Return on Equity | 312.48% | -1.81% | Guardant Health |
| Return on Assets (TTM) | -19.57% | 4.31% | Charles River |
| Free Cash Flow (TTM) | $-274.94M | $501.61M | Charles River |
| 1-Year Return | 177.35% | -8.03% | Guardant Health |
| Price-to-Sales Ratio (TTM) | 9.33 | 1.81 | Charles River |
| Enterprise Value | $8.54B | $9.89B | Charles River |
| EV/Revenue Ratio | 10.31 | 2.45 | Charles River |
| Gross Profit Margin (TTM) | 65.01% | 34.59% | Guardant Health |
| Revenue per Share (TTM) | $7 | $80 | Charles River |
| Earnings per Share (Diluted) | $-3.46 | $-1.29 | Charles River |
| Beta (Stock Volatility) | 1.46 | 1.47 | Guardant Health |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Guardant Health vs Charles River Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Guardant Health | -1.90% | 2.13% | -7.59% | 22.48% | 41.32% | 93.45% |
| Charles River | 2.86% | 20.46% | 8.75% | 11.35% | 17.47% | -3.99% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Guardant Health | 177.35% | 10.24% | -43.19% | 110.48% | 110.48% | 110.48% |
| Charles River | -8.03% | -14.57% | -27.68% | 171.42% | 438.76% | 310.82% |
News Based Sentiment: Guardant Health vs Charles River
Guardant Health
News based Sentiment: POSITIVE
Guardant Health delivered a strong Q2 performance with revenue exceeding expectations and raised full-year guidance. A significant legal victory and key partnerships further bolster the company's position, though continued cash burn remains a concern. These developments suggest a positive trajectory for the company, making October a significant month for investors.
Charles River
News based Sentiment: POSITIVE
The month of October saw a continuation of positive momentum for Charles River Laboratories, driven by multiple analyst upgrades and increased price targets following a strong Q2 earnings report. While some insider selling and mixed institutional activity exist, the overall narrative is one of growing optimism and potential for further growth.
Performance & Financial Health Analysis: Guardant Health vs Charles River
| Metric | GH | CRL |
|---|---|---|
| Market Information | ||
| Market Cap | $7.73B | $7.23B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 2,782,030 | 990,510 |
| 90 Day Avg. Volume | 2,486,587 | 826,430 |
| Last Close | $61.46 | $175.36 |
| 52 Week Range | $20.14 - $68.00 | $91.86 - $230.02 |
| % from 52W High | -9.62% | -23.76% |
| All-Time High | $181.07 (Feb 08, 2021) | $460.21 (Sep 20, 2021) |
| % from All-Time High | -66.06% | -61.90% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.31% | 0.01% |
| Quarterly Earnings Growth | 0.31% | -0.44% |
| Financial Health | ||
| Profit Margin (TTM) | -0.50% | -0.02% |
| Operating Margin (TTM) | -0.46% | 0.17% |
| Return on Equity (TTM) | 3.12% | -0.02% |
| Debt to Equity (MRQ) | -4.37 | 82.04 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-2.45 | $68.14 |
| Cash per Share (MRQ) | $4.19 | $3.72 |
| Operating Cash Flow (TTM) | $-238,546,000 | $787.45M |
| Levered Free Cash Flow (TTM) | $-131,174,000 | $706.38M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | $0.00 |
Valuation & Enterprise Metrics Analysis: Guardant Health vs Charles River
| Metric | GH | CRL |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -17.45 | 681.33 |
| Forward P/E | -22.87 | 14.30 |
| PEG Ratio | 3.66 | -17.28 |
| Price to Sales (TTM) | 9.33 | 1.81 |
| Price to Book (MRQ) | -25.24 | 2.16 |
| Market Capitalization | ||
| Market Capitalization | $7.73B | $7.23B |
| Enterprise Value | $8.54B | $9.89B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 10.31 | 2.45 |
| Enterprise to EBITDA | -20.38 | 10.35 |
| Risk & Other Metrics | ||
| Beta | 1.46 | 1.47 |
| Book Value per Share (MRQ) | $-2.45 | $68.14 |
Financial Statements Comparison: Guardant Health vs Charles River
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | GH | CRL |
|---|---|---|
| Revenue/Sales | $203.47M | $984.17M |
| Cost of Goods Sold | $74.72M | $666.44M |
| Gross Profit | $128.75M | $317.73M |
| Research & Development | $88.52M | N/A |
| Operating Income (EBIT) | $-111.04M | $74.67M |
| EBITDA | $-83.84M | $184.23M |
| Pre-Tax Income | $-94.87M | $35.98M |
| Income Tax | $290,000 | $10.10M |
| Net Income (Profit) | $-95.16M | $25.88M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | GH | CRL |
|---|---|---|
| Cash & Equivalents | $698.57M | $229.36M |
| Total Current Assets | $927.03M | $1.51B |
| Total Current Liabilities | $225.75M | $1.05B |
| Long-Term Debt | $1.28B | $2.99B |
| Total Shareholders Equity | $-250.79M | $3.24B |
| Retained Earnings | $-2.67B | $1.84B |
| Property, Plant & Equipment | $140.50M | $402.91M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | GH | CRL |
|---|---|---|
| Operating Cash Flow | $-49.41M | $130.09M |
| Capital Expenditures | $-4.46M | N/A |
| Free Cash Flow | $-67.15M | $112.37M |
| Debt Repayment | N/A | $-149.39M |
| Common Stock Repurchase | $-45.01M | $-353.13M |
Short Interest & Institutional Ownership Analysis
| Metric | GH | CRL |
|---|---|---|
| Shares Short | 8.74M | 2.56M |
| Short Ratio | 3.67 | 3.38 |
| Short % of Float | 0.07% | 0.06% |
| Average Daily Volume (10 Day) | 2,782,030 | 990,510 |
| Average Daily Volume (90 Day) | 2,486,587 | 826,430 |
| Shares Outstanding | 123.99M | 51.14M |
| Float Shares | 119.85M | 48.62M |
| % Held by Insiders | 0.04% | 0.01% |
| % Held by Institutions | 0.99% | 1.06% |
Dividend Analysis & Yield Comparison: Guardant Health vs Charles River
| Metric | GH | CRL |
|---|---|---|
| Last 12-Month Dividend | N/A | $0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | $0.00 |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | $0.00 |
| Ex-Dividend Date | N/A | N/A |